TCEAL7 (transcription elongation factor A like 7) functions as a tumor suppressor gene that negatively regulates multiple oncogenic pathways. The protein primarily acts as a transcriptional repressor by associating with the cyclin D1 promoter containing Myc E-box sequences and transcriptionally repressing cyclin D1 expression 1. TCEAL7 also negatively regulates the NF-κB pathway at the basal level by modulating transcriptional activity of NF-κB on target gene promoters, without affecting cytoplasmic NF-κB signaling 2. Additionally, TCEAL7 inhibits the Wnt/β-catenin pathway by blocking β-catenin translocation from cytoplasm to nucleus 3. TCEAL7 is frequently downregulated in multiple human cancers including ovarian 1, endometrial 4, gastric 5, and non-small cell lung cancer 6. This downregulation promotes anchorage-independent cell growth, enhances DNA-binding activity of Myc-Max, and upregulates pro-proliferative, pro-angiogenic, and anti-apoptotic genes 12. Clinically, decreased TCEAL7 expression is associated with poor prognosis in gastric adenocarcinoma patients and serves as an independent risk factor for survival 5. The gene is also regulated by microRNAs, with miR-182 and miR-301a targeting TCEAL7 and promoting tumor progression 43.